Target Hospitality (TH)
(Delayed Data from NSDQ)
$11.10 USD
-0.03 (-0.22%)
Updated May 7, 2024 04:00 PM ET
After-Market: $11.10 0.00 (0.00%) 6:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
TH 11.10 -0.03(-0.22%)
Will TH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TH
Xponential Fitness (XPOF) Q1 Earnings Miss Estimates
Target Hospitality (TH) Surges 6.5%: Is This an Indication of Further Gains?
TH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Target Hospitality (TH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
What's in Store for Target Hospitality (TH) in Q4 Earnings?
Lindblad Expeditions (LIND) Reports Q4 Loss, Misses Revenue Estimates
Other News for TH
Target Hospitality Q1 2024 Earnings Preview
Private Capital Management's Strategic Acquisition in PowerFleet Inc
Target Hospitality Announces First Quarter 2024 Earnings Release and Conference Call Schedule
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
TARGET HOSPITALITY ANNOUNCES FORMATION OF A SPECIAL COMMITTEE OF INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS